GlaxoSmithKline (GSK) has said that it expects minimal sales of Avandia in future after European regulators said the diabetes pill should be withdrawn from the market and America's medicines watchdog placed major restrictions on the drug.
The almost simultaneous rulings from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) marked an attempt to draw a line under the debate over the safety of Avandia, which has dogged GSK for three years.
For more: Glaxo's Avandia drug pulled from Europe - Telegraph
No comments:
Post a Comment